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transplantation is the development of bronchiolitis
obliterans syndrome (BOS), which is the manifestation
of chronic rejection. BOS has become the leading cause
of late morbidity and mortality after lung transplanta-
tion. BOS is defined clinically as the progressive loss of
pulmonary function in the absence of infection or acute
rejection. Histologically, obliterative bronchiolitis is
characterized by small airway inflammation and dense
fibrosis of the lamina propria and lumen with some
degree of interstitial fibrosis.1 Although the etiology of
BOS is unknown and may possibly be multifactorial,
most investigators agree that it is the sequelae of the
recipient immune response against the lung allograft.
BOS after lung transplantation was first reported in
1968 in a canine transplant model.2 One paradigm holds
that the epithelium, endothelium, or both are injured by
the immune response against the allograft and the sub-
sequent repair and tissue remodeling results in BOS.3
L ung transplantation has become a viable therapeuticalternative for the treatment of end-stage pulmonary
disease. The obstacle to the long-term success of lung
Objective: Development of anti-HLA antibodies is associated with devel-
opment of bronchiolitis obliterans syndrome after lung transplantation.
We sought to determine the mechanism by which anti-HLA antibodies
affect the development of bronchiolitis obliterans syndrome. We postu-
lated that anti-HLA antibodies bind to the donor lung epithelium and
stimulate phosphorylation and proliferation. Methods: The A549 lung
epithelial carcinoma cell line was cultured in serum-deficient medium to
produce static growth. Then the cells were treated with anti-HLA sera
from lung transplant recipients, pooled anti-HLA serum from highly
sensitized patients, or normal human serum. The cells were also treated
with the W6/32 mouse anti-HLA class I monoclonal antibody or control
mouse IgG. Tritiated thymidine uptake was determined at 24, 48, and 72
hours. In parallel experiments the cells were treated as described above,
and the levels of tyrosine phosphorylation were determined by Western
blot analysis. Results: Cells treated with anti-HLA serum or the W6/32
monoclonal antibody exhibited significantly greater proliferation and
tyrosine phosphorylation of proteins of approximately 170, 130, 110,
and 70 kd compared with cells treated with normal human serum or
mouse IgG, respectively. Conclusions: These data indicate that anti-HLA
antibodies have the ability to stimulate airway epithelial cell prolifera-
tion and that they may play an important role in the development of
bronchiolitis obliterans syndrome. Prevention of HLA sensitization and
immunosuppression with agents capable of blocking indirect antigen
presentation and the humoral immune response against the allograft
may be pivotal in preventing the development of bronchiolitis obliterans
syndrome after lung transplantation. (J Thorac Cardiovasc Surg
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ANTI-HLA ANTIBODY BINDING TO HLA CLASS I MOLECULES INDUCES PROLIFERATION OF AIRWAY
EPITHELIAL CELLS: A POTENTIAL MECHANISM FOR BRONCHIOLITIS OBLITERANS SYNDROME
Previous studies have linked the development of anti-
HLA antibodies with chronic rejection of both heart
and renal allografts.4,5 In this regard, previous studies
from our group have shown that HLA-A mismatch and
the development of anti-HLA class I antibodies after
lung transplantation correlate with the earlier develop-
ment of BOS.6,7 A more recent multicenter retrospec-
tive study also showed that the number of HLA-DR and
HLA-A mismatches independently predicted the 1-
year mortality rate after lung transplantation.8 In addi-
tion, the total number of HLA mismatches indepen-
dently predicted 3- and 5-year mortality rates after lung
transplantation. However, other clinical parameters had
a stronger effect in predicting the mortality rate 5 years
after lung transplantation.8
The chronic rejection of solid organ allografts appears
to share similar properties. Each syndrome of rejection
is characterized by a progressive deterioration of organ
function with gradual fibrosis of the graft vasculature
and parenchyma. The mechanism by which anti-HLA
antibodies may result in the changes seen in chronic
rejection in heart and renal allografts has not been elu-
cidated. In addition, a causal relationship between the
development of anti-HLA antibodies and BOS is yet to
be defined. Recent studies have shown that binding of
anti-HLA class I antibodies stimulates tyrosine phos-
phorylation and proliferation of endothelial cells.9,10
The studies described herein also show that binding of
anti-HLA class I antibodies to airway epithelial cells
(AECs) also induces intracellular signal transduction,
which results in tyrosine phosphorylation and prolifer-
ation. The studies described herein indicate that anti-
HLA antibodies may contribute to the development of
BOS by binding to HLA class I molecules in the lung
allograft epithelium and may directly activate these
cells to produce fibrogenic growth factors in situ,
resulting in the typical histopathology observed in
obliterative bronchiolitis.
Methods
Cells. The A549 lung epithelial carcinoma cell line was
obtained from the American Type Culture Collection
(Manassas, Va).
Serum samples. Pooled anti-HLA serum was obtained
from 10 patients awaiting kidney transplantation with 100%
reactivity against a reference panel consisting of lymphocytes
from 50 unrelated individuals of known HLA antigen speci-
ficity. Anti-HLA+ sera from lung transplant recipients who
had BOS at the time of the study (patients 1, 2, and 3) and
anti-HLA– sera from patients who were free of BOS at the
time of the study (patients 4, 5, 6, and 7) were used. AB Rh+
normal human serum (NHS) was obtained from C-six
Diagnostics (Germantown, Wis). All the lung transplant
recipients included in this study were anti-HLA– before the
transplant. Anti-HLA antibody reactivity was determined by
standard microcytoxicity assays. All of the sera were heat
inactivated at 56°C for 30 minutes.
Antibodies. The W6/32 mouse IgG monoclonal antibody
specific for a framework determinant on the HLA class I mol-
ecule was obtained from the American Type Culture
Collection. Mouse IgG, used as isotype control, was obtained
from Jackson ImmunoResearch Laboratories (West Grove,
Pa).
Western blotting for phosphotyrosine. The A549 cells
were grown to 75% confluence in RPMI-1640 medium
(Sigma, St Louis, Mo) supplemented with 15% fetal bovine
serum (Biocell Laboratories, Rancho Dominguez, Calif), 25
mmol/L N-[2-hydroxyethyl]piperazine-N-[2-ethanesulfonic
acid], 1 mmol/L sodium pyruvate, 2 mmol/L glutamine, 10
U/mL penicillin, and 10 µg/mL streptomycin (complete
medium). After 24 hours, the medium was replaced with
RPMI-1640 medium containing 1% fetal bovine serum (star-
vation medium). After 48 hours, the cells were harvested, and
5 × 105 cells were placed in Eppendorf tubes. The samples
were then treated for 5 and 10 minutes at 37°C, with starva-
tion medium containing the W6/32 monoclonal antibody (10
µg/mL), mouse IgG (10 µg/mL), anti-HLA serum (1:4), or
NHS (1:4). The tyrosine phosphorylation reactions were
stopped by the addition of tris-hydroxymethyl-amino
methane (TRIS)-buffered saline containing 5 µg/mL apro-
tinin, 10 µg/mL leupeptin, 10 µg/mL pepstatin, 2 mmol/L
phenylmethylsulfonyl fluoride, 4 mmol/L ethylenediamine
tetraacetic acid, 0.5 mmol/L zinc chloride, and 1 mmol/L
sodium orthovanadate (stop buffer). The cells were washed
once in stop buffer and then lysed in Laemmli sample buffer.
The samples were then boiled for 5 minutes and centrifuged
for 10 minutes at 14,000g. The samples were then elec-
trophoresed under reducing conditions in a 4% to 20% gradi-
ent sodium dodecylsulfate–polyacrylamide gel electrophore-
sis. The gel was transferred to a nitrocellulose membrane and
blocked in TRIS-buffered saline containing 0.5% Tween-20
and 5% bovine serum albumin for 1 hour. The membranes
were then immunoblotted with the PY20 antiphosphotyrosine
monoclonal antibody (1:1000) (Transduction Laboratories,
Lexington, Ky) or the MOPC monoclonal antibody as isotype
control (ICN Pharmaceuticals, Costa Mesa, Calif) for 1 hour.
The membranes were then washed (3×) and blocked in TRIS-
buffered saline containing 0.5% Tween-20 and 5% nonfat dry
milk. After 1 hour, the membranes were incubated with
horseradish peroxidase–conjugated goat anti-mouse IgG
(1:5000; Organon Teknika, Durham, NC) for 1 hour. The
membranes were then washed (3×), and the reaction was
visualized by using the ECL Western Blot detection system
according to the manufacturer’s instructions (Amersham,
Buckinghamshire, England).
Before blocking, the nitrocellulose membranes were
stained with Ponceau-S to verify equivalent protein loading
in each lane. The membranes immunoblotted with the MOPC
monoclonal antibody were developed in an identical manner
as the membranes immunoblotted with the PY-20 monoclon-
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al antibody. The immunoblotting with the MOPC monoclon-
al antibody did not reveal any specific bands in any of the
samples (data not shown).
Proliferation assay. The A549 cells were seeded in 96-
well, flat-bottom plates at 1 × 103 cells per well in quadrupli-
cate in complete medium. After 24 hours, the medium was
replaced with starvation medium. After 48 hours, the cells
were incubated in starvation medium containing the W6/32
anti-HLA monoclonal antibody (10 µg/mL), control mouse
IgG (10 µg/mL), anti-HLA serum (1:20), NHS (1:20), or
anti-HLA+ and anti-HLA– sera from lung transplant recipi-
ents (1:20). Cultures incubated in complete medium were
used as positive controls. The cells were then incubated for
24, 48, and 72 hours. Tritiated thymidine (1 µCi/well) (ICN
Pharmaceuticals) was added for the last 24 hours of incuba-
tion. At the end of the incubation period, the cultures were
harvested onto solid phase filters, and the tritiated thymidine
uptake was measured in a Wallac Microbeta Plus scintillation
counter (Wallac, Gathersburg, Md). The tritiated thymidine
uptake was expressed as counts per minute.
Statistical analysis. Statistical analysis of the data was car-
ried out by means of the Student t test.
Results
Induction of tyrosine phosphorylation by anti-
HLA antibody binding. Western blot analysis was
performed to determine whether binding of anti-HLA
antibodies to the surface of the A549 airway epithelial
cell line causes signal transduction mediated by tyro-
sine phosphorylation of intracellular proteins.
Treatment of A549 cells with the W6/32 monoclonal
antibody for 5 minutes induced tyrosine phosphoryla-
tion of proteins of approximately 170, 130, and 110 kd
when compared with the cells treated with control
mouse IgG (Fig 1). There is also a small increase in the
phosphorylation of a protein of approximately 70 kd
(Fig 1). After 10 minutes, binding of the W6/32 mono-
clonal antibody induced increased phosphorylation of
the same 70-kd protein (Fig 2). The 130- and 110-kd
proteins were no longer phosphorylated, and the 170-
kd protein is substantially less tyrosine phosphorylated
compared with that undergoing the 5-minute treatment
(Fig 2). Increased tyrosine phosphorylation was not
detected in cells treated with the control mouse IgG
compared with cells treated with starvation medium
alone (data not shown).
Treatment of A549 cells with the pooled anti-HLA
serum for 5 minutes also resulted in increased tyrosine
phosphorylation of proteins of approximately 170, 130,
110, and 70 kd when compared with cells treated with
NHS (Fig 1). After 10 minutes, the 170-kd protein
remains highly phosphorylated, and the 70-kd protein
shows a marked increase in tyrosine phosphorylation
(Fig 2). Increased tyrosine phosphorylation was not
detected in cells treated with NHS compared with cells
treated with starvation medium alone (data not shown).
Induction of proliferation by anti-HLA antibody
binding. The tritiated thymidine uptake of A549 cells
treated with the W6/32 monoclonal antibody resulted
in a markedly increased uptake when compared with
cells treated with the control mouse IgG (P = .006, P =
.0008, and P = .01 on days 1, 2, and 3, respectively)
(Fig 3). On day 2, a significant difference of tritiated
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Fig 1. Induction of tyrosine phosphorylation by anti-HLA
antibody binding. A549 cells were incubated for 5 minutes in
the presence of control mouse IgG (lane 1), W6/32 mono-
clonal antibody (lane 2), NHS (lane 3), and pooled anti-HLA
serum (lane 4). Cell samples were then analyzed by
immunoblotting with the PY20 antiphosphotyrosine mono-
clonal antibody. The results are representative of 2 different
experiments.
Fig 2. Induction of AEC tyrosine phosphorylation by anti-
HLA antibody binding. A549 cells were incubated for 10
minutes in the presence of control mouse IgG (lane 1),
W6/32 monoclonal antibody (lane 2), NHS (lane 3), and
pooled anti-HLA serum (lane 4). Cell samples were then ana-
lyzed by immunoblotting with the PY20 antiphosphotyrosine
monoclonal antibody. The results are representative of 2 dif-
ferent experiments.
thymidine uptake was observed between cells treated
with the W6/32 monoclonal antibody and cells treated
with complete medium (P = .001) (Fig 3).
To determine whether serum from patients sensitized
against the HLA molecule would induce similar prolif-
eration in the AECs, we incubated these A549 cells
with the pooled anti-HLA serum from 10 patients with
high reactivity against the HLA molecule. This treat-
ment induced a significantly increased tritiated thymi-
dine uptake when compared with cells treated with
NHS (P = .005, P = .01, and P = .01 on days 1, 2, and
3, respectively). In fact, the addition of the pooled anti-
HLA serum had greater proliferative capability when
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Fig 3. Stimulation of AEC proliferation by the W6/32 mono-
clonal antibody. A549 cells were starved for 48 hours and
then incubated in the presence of the W6/32 monoclonal anti-
body, control mouse IgG (negative control), or complete
medium (positive control) for 24, 48, and 72 hours. Cell pro-
liferation was determined by tritiated thymidine incorpora-
tion. The results of quadruplicate cultures (n = 4) are
expressed as the mean values ± SD and are representative of
3 different experiments. *P < .05.
Fig 4. Stimulation of AEC proliferation by the pooled anti-
HLA serum. A549 cells were starved for 48 hours and then
incubated in the presence of the pooled anti-HLA serum,
NHS (negative control), or complete medium (positive con-
trol) for 24, 48, and 72 hours. Cell proliferation was deter-
mined by tritiated thymidine incorporation. The results of
quadruplicate cultures (n = 4) are expressed as the mean val-
ues ± SD and are representative of 3 different experiments.
*P < .05.
Fig 5. Stimulation of AEC proliferation by anti-HLA+ sera
from lung transplant recipients with BOS at the time of the
study. A549 cells were starved for 48 hours and then incubat-
ed in the presence of anti-HLA+ sera from lung transplant
recipients with BOS at the time of the study, pooled anti-
HLA serum (positive control), or NHS (negative control) for
24, 48, and 72 hours. Cell proliferation was determined by
tritiated thymidine incorporation. The results of quadrupli-
cate cultures (n = 4) are expressed as the mean values ± SD
and are representative of 3 different experiments.
Fig 6. Lack of stimulation of AEC proliferation by anti-HLA–
sera from lung transplant recipients without BOS at the time
of the study. A549 cells were starved for 48 hours and then
incubated in the presence of anti-HLA– sera from lung trans-
plant recipients without BOS at the time of the study, pooled
anti-HLA serum, or NHS for 24, 48, and 72 hours. Cell pro-
liferation was determined by tritiated thymidine incorpora-
tion. The results of quadruplicate cultures (n = 4) are
expressed as the mean values ± SD and are representative of
3 different experiments.
compared with complete medium (P = .003, P = .002,
and P = .0002 on days 1, 2, and 3, respectively) (Fig 4).
The maximum effect of both the W6/32 monoclonal
antibody and the pooled anti-HLA serum occurred on
day 2 (Figs 3 and 4).
More significantly, posttransplant serum from lung
allograft recipients who were either anti-HLA+ or anti-
HLA– also had similar effects. Anti-HLA+ sera from
lung transplant recipients with BOS at the time of the
study induced an increased tritiated thymidine uptake
when compared with NHS, but the difference did not
reach statistical significance (P = .1, P = .2, and P = .2
on days 1, 2, and 3, respectively) (Fig 5). It is notewor-
thy that these patients were sensitized only by the
donor HLA, whereas the individuals who contributed
to the pooled anti-HLA serum were sensitized by mul-
tiple blood transfusions and were not receiving an
immunosuppression regimen at the time of the blood
collection. Hence lung transplant recipient sera had a
decreased antibody concentration that was donor HLA
specific. On the contrary, anti-HLA– sera from lung
transplant recipients without BOS at the time of the
study induced tritiated thymidine uptake comparable
with that of NHS (Fig 6). Comparison of the anti-HLA+
lung transplant recipient group with the anti-HLA–
lung transplant recipient group revealed statistically
significant differences on days 1 and 2 (P = .006 and P
= .00002, respectively).
Discussion
Chronic rejection, which is responsible for the major-
ity of late graft failures, is defined as progressive func-
tional deterioration of the transplanted organ occurring
months or years after engraftment. It is associated with
vascular obliteration and other architectural changes
that lead to a gradual fibrosis.10 The target of the
immune response to lung allografts has not been defin-
itively determined. In both renal and cardiac allografts
the vascular endothelium appears to be intimately
involved in chronic rejection. However, the epithelium
of both kidney and liver allografts also appears to be
involved. In renal and hepatic transplantation, one
manifestation of chronic rejection is the disappearance
of the renal tubules and the bile ducts, both of which
are lined by epithelium.3,11,12 Several studies have
implicated the bronchial epithelium as the target for the
chronic rejection process after lung transplantation, a
role not unlike the one played by the vascular endothe-
lium in cardiac and renal allografts.13,14
The expression of major histocompatibility complex
(MHC) class II antigens on the bronchial epithelium
has been postulated to be the stimulus for BOS.15 AECs
constitutively express HLA class I and are capable of
HLA class II expression in the setting of inflammation
or immunologic activation.16,17 In a rat model both
MHC class I and II molecules are upregulated in reject-
ing lung allografts.14,18 BET-1A, a human AEC line,
upregulates the expression of intercellular adhesion
molecule 1 and both MHC class I and II antigens after
exposure to interferon-γ.13 AECs do not present antigen
in the context of HLA as efficiently as pulmonary
macrophages, but they have been reported to augment
the antigen presenting function of macrophages.19 In
addition, an increased number of dendritic cells are
associated with the bronchial epithelium in rejecting
allografts.4 Because dendritic cells are among the most
efficient antigen presenting cells, this increased popu-
lation of dendritic cells would compensate for poor
antigen presentation by the bronchial epithelium.
HLA antigens are suspected to be the major stimulus
for chronic rejection because recipients with mismatch
at both the HLA class I and II loci have decreased graft
survival.20 The expression of MHC class II antigens on
the bronchial epithelium has been postulated to be the
major stimulus for BOS.15 However, allografts with mis-
matches only at the HLA class I loci can stimulate a
complete T cell–dependent immune response.21
Mismatched HLA class I peptides have been shown to
be recognized by the recipient CD4+ T cell through the
indirect pathway.22 In fact, reactivity against mis-
matched HLA class I antigens carries a worse prognosis
for lung transplant recipients.23-25 HLA class II–reactive
lymphocytes are reported to be associated with steroid-
responsive BOS, whereas HLA class I–reactive lympho-
cytes are associated with a treatment-resistant
course.23-25 CD4+ T cells that recognize HLA class I
mismatches through the indirect pathway can contribute
to allograft rejection by providing the cytokines neces-
sary for stimulation of B cells, resulting in a specific
anti-HLA class I humoral immune response.21,22
Chronic rejection in many experimental models and
clinical scenarios is associated with the development of
anti-HLA antibodies.9 Antibody-mediated rejection has
been reported in both heart and kidney allografts.26
Recent studies in the rat model have noted the potential
role of T cell–dependent humoral immune response in
MHC class I–disparate allograft rejection.27 HLA class
I mismatch and the development of anti-HLA antibod-
ies have been linked with early onset of BOS.6,7 The
results presented in this study (Figs 1 and 2), as well as
those in a report by Bian and colleagues9 indicate that
signal transduction involving tyrosine phosphorylation
may play a vital role in epithelial cell activation by
anti-HLA antibodies. Furthermore, anti-HLA antibody
binding to AECs also induces intracellular calcium
influx in AECs (unpublished observations, May 1999).
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Although HLA class I molecules are not associated
with G proteins and do not have tyrosine kinase activi-
ty, MHC class I molecules have been shown to be able
to transduce intracellular signals, which can result in
cellular proliferation.28-30
We have shown herein that anti-HLA antibody bind-
ing to AECs induces proliferation in the near absence
of growth factors present in the starvation media. This
suggests that the signaling pathway activated by the
anti-HLA antibodies may induce the production of
growth factors or may allow the cells to use the avail-
able growth factors more efficiently. In this regard,
Harris and colleagues10 have recently reported that
endothelial cells upregulate the expression of fibroblast
growth factor receptor when treated with the W6/32
monoclonal antibody.
Treatment with pooled anti-HLA serum had a greater
proliferative effect than treatment with the W6/32 mono-
clonal antibody. The polyvalent nature of the anti-HLA
antibodies in the pooled anti-HLA serum is the most
plausible explanation for this effect. In addition, the
intrinsic growth factors present in human serum may
also explain the increased proliferation of A549 cells
when treated with NHS compared with complete medi-
um (Fig 4).
More significantly, anti-HLA antibodies that devel-
oped after lung transplantation also induced increased
proliferation of AECs but not at the same level as the
highly reactive pooled anti-HLA serum (Fig 5). In con-
trast, the anti-HLA– sera from lung transplant recipi-
ents without BOS at the time of the study induced pro-
liferation comparable with that of NHS (Fig 6). This
indicates that the proliferative effect induced by the
anti-HLA+ sera from lung transplant recipients with
BOS at the time of the study is due to the direct effect
of the anti-HLA antibodies and not a result of the
immunosuppressive agents, such as corticosteroids,
which can act as growth factors in culture.
In summary, the data presented in this study show
that anti-HLA antibodies bind to AECs and stimulate
tyrosine phosphorylation of intracellular proteins. The
ligation of the MHC class I molecules transduces an
intracellular signal, which ultimately results in
increased proliferation of the A549 cells in the absence
of growth factors. The pathway that leads from signal
transduction at the cell membrane to cellular prolifera-
tion is yet to be elucidated. It has been shown that
AECs can produce mesenchymal growth factors.13
These growth factors could act in an autocrine and a
paracrine fashion to stimulate the proliferation of
AECs, as well as fibroblasts and smooth muscle cells,
which could ultimately result in the tissue remodeling
observed in obliterative bronchiolitis developed after
lung transplantation. Current studies in our laboratory
are focused on determining whether binding of anti-
HLA antibodies to AECs also induces an increased
production of fibrogenic growth factors. The identifica-
tion of a growth factor or factors for fibroblasts and
smooth muscle cells produced by AECs and upregulat-
ed by anti-HLA antibody binding may allow for early
intervention and successful treatment of BOS before
any significant lesions develop in the bronchi, leading
to reduction of pulmonary function in lung transplant
recipients.
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Discussion
Dr Dao M. Nguyen (Bethesda, Md). I have one question.
You showed that the P170 protein band has the tyrosine phos-
phorylation. Did you have a chance to characterize that pro-
tein? Is that an epidermal growth factor receptor?
Dr Reznik. That is one of the possibilities. These studies
are very preliminary. We have some postulated identities for
various hyperphosphorylated bands, and the epidermal
growth factor receptor is one of the possibilities for the 170-
kd band.
Dr Nguyen. Are you planning to use a tyrosine kinase
inhibitor to determine whether you can downregulate this
pathway?
Dr Reznik. We are currently working on it.
Dr Valerie W. Rusch (New York, NY). Why did you use the
A549 cell line and why is that relevant to a lung transplant
model?
Dr Reznik. We used A549 in our pilot studies to work out
this experimental system. A549 has been used by many inves-
tigators studying the biology of the lung epithelium.
However, we also have preliminary data obtained with pri-
mary bronchial epithelial cell lines that we developed from
our lung donors, and we have similar results, including the
tyrosine phosphorylation assays. The primary epithelial cell
lines grow very slowly so that it is difficult to measure differ-
ences in proliferation assays.
Dr Rusch. Are those short-term cultures that you have
established?
Dr Reznik. We use both primary cell cultures and SV40
transformed cell lines, because the primary airway epithelial
lines only last 4 or 5 passages.
Dr Rusch. I wonder about this because this is a bron-
choalveolar or adenocarcinoma cell line, which may not be
relevant to a benign lung model.
Dr Reznik. A549 is derived from a lung epithelial carci-
noma. We are, however, also concerned about the differences
between transformed cells and benign lung epithelial cells.
As I mentioned, the salient points of our results were con-
firmed by using primary cell lines.
Dr Scott J. Swanson (Boston, Mass). Have you been able
to demonstrate a correlation between HLA mismatching and
the development of BOS in your clinical trials?
Dr Reznik. Our group has recently reported the outcome
of lung transplant recipients who are having mismatches at
the HLA-A locus (Sundaresan et al. Transplantation
1998;65:648-53). Furthermore, we have shown that produc-
tion of antibodies against HLA correlates with the develop-
ment of BOS (Smith et al. J Thorac Cardiovasc Surg 1998;
116:812-20; Jaramillo et al. Transplant Proc 1999;31:185-6).
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